title: How long can continuous ambulatory peritoneal dialysis be continued?
abstract: We investigated how long continuous ambulatory peritoneal dialysis (CAPD) could be continued in the face of peritoneal sclerosis. 15 CAPD patients with no experience of peritonitis were selected and the time limitation for CAPD was examined retrospectively, based on the dialysate osmolality, serum creatinine concentration, etc.. The values for the dialysate osmolality and serum creatinine concentration increased gradually with the duration of CAPD and were significantly increased from 6 months. 5 patients whose serum creatinine concentration during the first 6 months after initiation of CAPD increased more than 5 mg/dl, could not continue CAPD for more than 24 months because of the appearance of peritoneal membrane failure. When the time limitation for CAPD was assessed in 10 stable patients, close relationships between the mean dialysate osmolality and duration of CAPD (Y = 0.52X + 351.25, r = 0.83, P < 0.01), and between the mean serum creatinine concentration and duration of CAPD (Y = 0.18X + 6.84, r = 0.95, P < 0.001) were recognized. If the practical limitation for CAPD was set at 400 mOsm/l in terms of the dialysate osmolality or 20 mg/dl in terms of serum creatinine concentration, its value became 94.1 months or 73.1 months, respectively. It is concluded that the time limitation for CAPD can be expected to be approximately 6 to 8 years in stable CAPD patients, and we need to resolve CAPD-induced problems involving the peritoneal membrane in order to continue CAPD for more than 10 years.
authors.affiliation: Nishi-Kofu National Hospital, Yamanashi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: F
authors.initials: F
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: M
authors.initials: M
authors.lastname: Yanai
authors.forename: T
authors.initials: T
authors.lastname: Kuno
authors.forename: Y
authors.initials: Y
authors.lastname: Nagura
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D015314:Dialysis Solutions; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011379:Prognosis; D013997:Time Factors; D014462:Ultrafiltration; D014556:Urine
chemical_list: D015314:Dialysis Solutions; D003404:Creatinine